What does Plug-and-Play offer large-scale AAV manufacturing?

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Adeno-associated viruses (AAV) are among the most common vectors used for ex-vivo and in-vivo gene therapies. Yet, despite hundreds of biotechnology and engineering studies, standard procedures for large-scale manufacturing of these vectors remains inconsistent.

AGC Biologics will discuss AAV-based gene therapy production, managing adherent and suspension processes, and new cost-effective and streamlined approaches for creating large-scale AAV production that can meet any product specification. This plug-and-play concept is built around using transient transfection with PEIpro, and an efficient and scalable off-the-shelf AAV vector production process that will get you to the manufacturing and clinical supply stage as quickly as possible, while reducing complex PD efforts.

Polyplus will share their commitment to viral vector manufacturers in manufacturing therapeutic AAVs with patient safety in mind. Scalable manufacturing of AAV, and viral vector in general, brings up two main challenges that need to be addressed to ensure compliance with cGMP regulations: sourcing of raw materials and management of the supply chain.

• Concepts for building a plug-and-play system for easier Largescale AAV Production and Manufacturing
• Solutions for addressing challenges with AAV adherent and suspension cell lines
• How to create cells lines and media scouting
• The importance of scale down models for process development
• How to ensure compliance with cGMP regulations for raw and starting materials used in AAV manufacturing

Margherita Neri

Vector process Development Manager at MolMed SpA

Margherita Neri is vector process development manager in MolMed. She joined MolMed in 2012 working in the Quality Control Unit and then in Development Unit. She gained knowledge and experience in the design of vector production processes. She is involved in the process development and industrialization of large scale production of lentiviral and AAV vectors in compliance to GMP requirements.She holds a degree in Pharmaceutical Biotechnology from Università degli Studi - Milano and a Ph.D. in molecular medicine with a study on gene therapy for lysosomal storage disorder.

Claire Wartel-Weill

Polyplus-transfection

Claire owns a Ph.D. in Molecular Pharmacology and Pharmacochemistry from the University of Strasbourg (France, 1999). After several post-docs in different prestigious universities, Claire joined Polyplus-transfection in 2004 as Cell Biology project leader and participated in the development of our flagship product jetPRIME®. Claire has taken Quality responsibility since 2007, and nowadays manages the department of Quality and Regulatory Affairs.

Watch now

SPEAKERS

Margherita Neri

Vector process Development Manager at MolMed SpA

Claire Wartel-Weill

Polyplus-transfection

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 69

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 40

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 34

Days

Register

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity

22 May

in 33

Days

Register

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

21 May

in 32

Days

Register